Monthly Archives: March 2016

BMS Secures The Keys To Padlock
March 23, 2016

Today we announced the acquisition of Padlock Therapeutics by BMS for up to $600M in total deal value (here), bringing a bittersweet end to a great startup story and the start of a promising and likely productive portfolio for BMS.

Leave a comment

Putting It In Reverse
March 18, 2016

This blog was written by Ron Renaud, CEO of RaNA Therapeutics, as part of the From The Trenches feature of LifeSciVC. Much of the discussion I have had had with my colleagues in publicly traded biotech companies over the last

Leave a comment

Is Biotech Ready For An Über Disruption?
March 15, 2016

This blog was written by Rosana Kapeller, CSO of Nimbus Therapeutics, as part of the From The Trenches feature of LifeSciVC. Love it or hate it, no one can deny that Über has revolutionized the fundamental nature of the taxi

1 Comment

Corporate Equity Investing In Biotech: Enriching For Success
March 10, 2016

For startup and emerging biotech companies, corporate venture capital and direct corporate equity investing are critically important contributors on the spectrum of funding sources – and over the past fifteen years, their involvement as investors in young biotech companies appears

Leave a comment

Look Beyond The Headlines: Tackling Ever-Present Challenge Of Antimicrobial Resistance
March 4, 2016

This blog was written by Ankit Mahadevia, CEO of Spero Therapeutics, as part of the From The Trenches feature of LifeSciVC. Infectious disease has had an ebb and flow relationship with our general awareness; epidemics such as Zika, Ebola, and

Leave a comment

Five Years Into the LifeSciVC Experiment
March 3, 2016

It’s hard to believe how time flies, but I started this LifeSciVC biotech-blogging experiment five years ago today. Since that initial post in March 2011, exactly 250 blogs have gone live, making it an opportune time to step back and

7 Comments

Entrepreneuring Post-Pharma
March 1, 2016

This blog was written by Jason Gardner, Atlas EIR and founding CEO of a new stealth-stage startup, as part of the From The Trenches feature of LifeSciVC. What are you doing? This is the most frequent yet simple question that

1 Comment